The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Aptose Signs Debt Conversion Agreement with Hanmi
Mar 28, 2025•about 1 year ago
Contract Type
agreement
San DiegoBiotechnologyHealth CareMedicalTherapeuticsresearch
Description
Aptose Biosciences Inc. announced a debt conversion agreement with Hanmi, as part of their corporate update. The agreement showcases the company's efforts to manage its financial position and pave the way for further developments in their clinical-stage precision oncology programs, particularly the tuspetinib-based triple drug frontline therapy for newly diagnosed acute myeloid leukemia (AML).
Company Information
Company
Aptose Biosciences
Location
12770 High Bluff Dr
San Diego, California, United States
About
Aptose Biosciences is a science-driven clinical-stage biotechnology company developing first-in-class targeted agents to address unmet clinical need in multiple hematologic malignancies.
San DiegoBiotechnologyHealth CareMedicalTherapeuticsresearch